Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 2
1997 22
1998 95
1999 77
2000 81
2001 107
2002 140
2003 154
2004 157
2005 197
2006 213
2007 241
2008 235
2009 245
2010 236
2011 285
2012 297
2013 334
2014 351
2015 338
2016 326
2017 267
2018 249
2019 275
2020 259
2021 267
2022 223
2023 212
2024 69

Text availability

Article attribute

Article type

Publication date

Search Results

5,436 results

Results by year

Filters applied: . Clear all
Page 1
Efavirenz: History, Development and Future.
Costa B, Vale N. Costa B, et al. Biomolecules. 2022 Dec 31;13(1):88. doi: 10.3390/biom13010088. Biomolecules. 2022. PMID: 36671473 Free PMC article. Review.
In 1998, the FDA authorized efavirenz for the treatment of HIV-1 infection. Patients formerly required three 200 mg efavirenz capsules daily, which was rapidly updated to a 600 mg tablet that only required one tablet per day. ...Efavirenz has been a primary f …
In 1998, the FDA authorized efavirenz for the treatment of HIV-1 infection. Patients formerly required three 200 mg efavirenz …
Efavirenz as a psychotropic drug.
Zareifopoulos N, Lagadinou M, Karela A, Pouliasi F, Economou I, Tsigkou A, Velissaris D. Zareifopoulos N, et al. Eur Rev Med Pharmacol Sci. 2020 Oct;24(20):10729-10735. doi: 10.26355/eurrev_202010_23433. Eur Rev Med Pharmacol Sci. 2020. PMID: 33155233 Free article. Review.
The purpose of this article is to review the psychotropic properties of efavirenz, which are the most important adverse events associated with the drug and commonly result in treatment discontinuation. ...Efavirenz interacts with many of the same molecular targets a …
The purpose of this article is to review the psychotropic properties of efavirenz, which are the most important adverse events associ …
Efavirenz.
Adkins JC, Noble S. Adkins JC, et al. Drugs. 1998 Dec;56(6):1055-64; discussion 1065-6. doi: 10.2165/00003495-199856060-00014. Drugs. 1998. PMID: 9878993 Review.
Clinically significant drug interactions have been reported with efavirenz and indinavir and saquinavir. An increase in dosage of indinavir from 800 to 1000 mg 3 times daily is recommended during coadministration with efavirenz. Use of efavirenz in combinatio …
Clinically significant drug interactions have been reported with efavirenz and indinavir and saquinavir. An increase in dosage of ind …
Efavirenz.
Maggiolo F. Maggiolo F. Expert Opin Pharmacother. 2007 Jun;8(8):1137-45. doi: 10.1517/14656566.8.8.1137. Expert Opin Pharmacother. 2007. PMID: 17516877 Review.
Efavirenz-based regimens have performed favorably compared with protease inhibitor-based therapies either in naive patients or as simplification strategies in pretreated subjects. Efavirenz is administered once-daily and its simple dosing schedule improves adherence …
Efavirenz-based regimens have performed favorably compared with protease inhibitor-based therapies either in naive patients or as sim …
Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
Wang PF, Neiner A, Kharasch ED. Wang PF, et al. Drug Metab Dispos. 2019 Oct;47(10):1195-1205. doi: 10.1124/dmd.119.086348. Epub 2019 Jul 19. Drug Metab Dispos. 2019. PMID: 31324697 Free PMC article. Review.
Metabolism of R-efavirenz by CYP2B6 remains unexplored. This investigation assessed S-efavirenz metabolism by clinically relevant CYP2B6 genetic variants. ...Rates of R-efavirenz metabolism were approximately 1/10 those of S-efavirenz for wild-type CYP …
Metabolism of R-efavirenz by CYP2B6 remains unexplored. This investigation assessed S-efavirenz metabolism by clinically relev …
A Concise Analytical Profile of Efavirenz: Analytical Methodologies.
Ambhore JP, Chaudhari SR, Cheke RS, Kharkar PS. Ambhore JP, et al. Crit Rev Anal Chem. 2022;52(7):1583-1592. doi: 10.1080/10408347.2021.1895711. Epub 2021 Mar 15. Crit Rev Anal Chem. 2022. PMID: 33722117 Review.
Therefore, the proposed review integrally addresses the analytical reports of efavirenz recorded in the literature databases like Scopus, Web of Science, Google Scholar, Pub-Med, and through many other sources. It has been remarked that for the development of efavirenz …
Therefore, the proposed review integrally addresses the analytical reports of efavirenz recorded in the literature databases like Sco …
Efavirenz and the CNS: what we already know and questions that need to be answered.
Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV. Apostolova N, et al. J Antimicrob Chemother. 2015 Oct;70(10):2693-708. doi: 10.1093/jac/dkv183. Epub 2015 Jul 22. J Antimicrob Chemother. 2015. PMID: 26203180 Review.
However, growing concern about its adverse effects has sometimes led to efavirenz being replaced by other drugs in the initial treatment selection or to switching of therapy to efavirenz-free regimens in experienced patients. ...The mechanisms responsible for efa …
However, growing concern about its adverse effects has sometimes led to efavirenz being replaced by other drugs in the initial treatm …
Efavirenz--still first-line king?
Best BM, Goicoechea M. Best BM, et al. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):965-72. doi: 10.1517/17425255.4.7.965. Expert Opin Drug Metab Toxicol. 2008. PMID: 18624683 Free PMC article. Review.
BACKGROUND: Efavirenz is a potent, safe and tolerable non-nucleoside reverse transcriptase inhibitor (NNRTI) recommended as initial therapy. ...METHODS: Published articles and conference presentations pertaining to efavirenz and/or the newer antiretroviral agents we …
BACKGROUND: Efavirenz is a potent, safe and tolerable non-nucleoside reverse transcriptase inhibitor (NNRTI) recommended as initial t …
Efavirenz: a decade of clinical experience in the treatment of HIV.
Maggiolo F. Maggiolo F. J Antimicrob Chemother. 2009 Nov;64(5):910-28. doi: 10.1093/jac/dkp334. Epub 2009 Sep 18. J Antimicrob Chemother. 2009. PMID: 19767318 Free PMC article. Review.
Efavirenz is more effective as a third agent than unboosted PIs or the nucleoside analogue abacavir. ...Efavirenz also retains a role after failure of a first PI-based regimen. ...
Efavirenz is more effective as a third agent than unboosted PIs or the nucleoside analogue abacavir. ...Efavirenz also retains …
Efavirenz: enhancing the gold standard.
Arribas JR. Arribas JR. Int J STD AIDS. 2003 Oct;14 Suppl 1:6-14. doi: 10.1258/095646203322491824. Int J STD AIDS. 2003. PMID: 14617398 Review.
The efficacy of efavirenz in these patient groups has been established in many clinical and cohort studies. Furthermore, efavirenz is now available as a single 600 mg tablet, providing a simplified therapy and decreased pill burden, which may lead to improved adhere …
The efficacy of efavirenz in these patient groups has been established in many clinical and cohort studies. Furthermore, efavirenz …
5,436 results